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Abstract
Kaposi sarcoma–associated herpesvirus (KSHV) is necessary but not sufficient to cause Kaposi sarcoma (KS). Coinfection
with human immunodeficiency virus type 1 (HIV-1), in the absence of antiretroviral suppressive therapy, drastically increases
the risk of KS. Previously, we identified that HIV-1 transactivative transcription protein (Tat) was an important cofactor that
activated lytic cycle replication of KSHV. Here, we further investigated the potential of Tat to influence tumorigenesis induced
by KSHV Kaposin A, a product of KSHV that was encoded by the open reading frame K12 (a KSHV-transforming gene). By
using colony formation in soft agar, 3H-TdR incorporation, cell cycle, and microarray gene expression analyses, we demon-
strated that Tat enhanced proliferation as well as mitogen-activated protein kinase, signal transducer and activator of tran-
scription 3, and phosphatidylinositol 3-kinase/protein kinase B signaling induced by Kaposin A in NIH3T3 cells. Animal
experiments further demonstrated that Tat accelerated tumorigenesis by Kaposin A in athymic nu/nu mice. Cells obtained
from primary tumors of nude mice succeeded inducing tumors in immunocompetent mice. These data suggest that Tat
can accelerate tumorigenesis induced by Kaposin A. Our data present the first line of evidence that Tat may participate in
KS pathogenesis by collaborating with Kaposin A in acquired immunodeficiency syndrome (AIDS)–related KS (AIDS-KS) pa-
tients. Our data also suggest that the model for Kaposin and Tat–mediated oncogenesis will contribute to our understand-
ing of the pathogenesis of AIDS-KS at themolecular level andmay even be important in exploring a novel therapeuticmethod
for AIDS-KS.
Neoplasia (2009) 11, 1272–1284
Abbreviations: AIDS-KS, acquired immunodeficiency syndrome (AIDS)-related KS; Akt, protein kinase B; cpm, counts per minute; ERK, extracellular signal–regulated protein
kinase; HIV-1, human immunodeficiency virus type 1; KS, Kaposi sarcoma; KSHV, Kaposi sarcoma–associated herpesvirus; PI3K, phosphatidylinositol 3-kinase; RT-PCR,
reverse transcription–polymerase chain reaction; STAT3, signal transducer and activator of transcription 3; Tat, transactivative transcription protein; VEGF, vascular endothelial
cell growth factor; vGPCR, viral G protein–coupled receptor
Address all correspondence to: Chun Lu, PhD, Department of Microbiology and Immunology, Nanjing Medical University, Nanjing 210029, PR China. E-mail: clu@njmu.edu.cn
1The authors thank the support from the National Natural Science Foundation of China (30670096 and 30972619 to C.L.; 30900064 to D.Q.), Fok Ying Tung Education
Foundation (101038 to C.L.), Program for New Century Excellent Talents in University of China (NCET-05-0506 to C.L.), the Ministry of Science and Technology of Jiangsu
Province (BK2006524 to C.L.), Program for Changjiang Scholars and Innovative Research Team in University of China (IRT0631), and the Ministry of Health of Jiangsu
Province (no. XK200731).
2The first four authors contributed equally to this work.
Received 18 March 2009; Revised 18 May 2009; Accepted 26 May 2009
Copyright © 2009 Neoplasia Press, Inc. All rights reserved 1522-8002/09/$25.00
DOI 10.1593/neo.09494
www.neoplasia.com
Volume 11 Number 12 December 2009 pp. 1272–1284 1272
Introduction
Kaposi sarcoma–associated herpesvirus (KSHV, also designated human
herpesvirus 8 or HHV-8) has been causally linked to the develop-
ment of Kaposi sarcoma (KS) [1]. The KS lesions are characterized by
proliferating spindle cells, prominent angiogenesis, hemorrhage, and
leukocyte infiltration. Although KSHV is necessary for the development
of KS, other factors may also play important roles in the pathogenesis
of this disease. One potentially important cofactor is human immuno-
deficiency virus type 1 (HIV-1). Individuals dually infected with KSHV
and HIV-1 have a greatly enhanced prevalence of KS compared with
those infected with KSHV alone [2]. Immune dysfunction likely ac-
counts for some of the increased incidence of KS in double infections,
but it may not be the sole contributing factor. For instance, studies in-
dicated that KS developed almost exclusively in HIV-1–positive, but
notHIV-2–positive, patients inGambia,West Africa, despite essentially
equivalent seroprevalence for KSHVand severity of immunosuppression
in both groups of patients [3]. In addition, acquired immunodeficiency
syndrome (AIDS)–related KS (AIDS-KS) has a more aggressive course
than other forms of KS, including those associated with iatrogenic
immunosuppression in transplant patients. Therefore, studies have con-
tinued to focus on other mechanisms, such as induction of cytokine ex-
pression and production of HIV-1–encoded proteins, particularly the
secreted HIV-1 protein, transactivative transcription protein (Tat). Pre-
vious studies indicated that Tat acted as a growth factor for KS-derived
endothelial cells [4,5], possibly in part through synergy with or dys-
regulation of the expression of proinflammatory cytokines [6–9]. Re-
cently, we showed that Tat was an important cofactor that activated
lytic cycle replication of KSHV bymodulating Janus kinase (JAK)/signal
transducer and activator of transcription (STAT) signaling [10]. Thus,
Tat promotes tumorigenesis of endothelial cells, both through stimula-
tion of vascular endothelial growth factors, antiapoptotic activity, and
KSHVreplication [11]. These data suggest a role of Tat in the pathogen-
esis of AIDS-KS.
KSHV genome contains open reading frames (ORFs) to code for
81 proteins, of which 66 are similar to other γ-herpesviruses and 15
are unique to KSHV. There are six genes that have been shown to possess
oncogenic properties in cell culture. They are ORF K1 (a glycoprotein),
ORF K9 (a viral interferon-regulatory factor),ORF74 (a viral G protein–
coupled receptor or vGPCR), ORF73 (latency-associated nuclear anti-
gen), ORF72 (viral cyclin), and ORF K12 (Kaposin). The first three
genes are transcribed during the lytic phase of KSHV replication, and
the rest are expressed during latency [12]. Specifically, Kaposin is ex-
pressed from T0.7 transcripts in latently infected cells, and messenger
RNA (mRNA) can be detected in earliest to advanced stages of KS le-
sions [13–15]. Studies demonstrated that the initiation of transcription
at the K12 locus is complex, with multiple transcripts of various lengths
being produced resulting in Kaposin A, B, and C forms with molecular
weights of 6.6, 38, and 54 kDa, respectively [16]. Because Kaposin A
is the predominant form in KSHV-infected cells, several groups have
used this form to investigate the transformation properties of this pro-
tein. It was demonstrated that Kaposin A induced transformation of
Rat-3 cells [17]. These transformed cells induced highly angiogenic, un-
differentiated sarcomas in athymic nude mice within 1 to 3 weeks [17].
Although the mechanisms of KS pathogenesis by KSHV are not
fully elucidated, an increasing body of evidence suggests that the
vGPCR plays an important role. It induces angiogenesis and vascular
endothelial growth factor (VEGF) expression in vitro and in vivo in
mice, and transgenic mice expressing vGPCRdevelop angioproliferative
lesions with many of the characteristics of KS [18–21]. Interestingly, by
inducing activation of nuclear factor of activated T cells (NF-AT) and
nuclear factor-kappaB (NF-κB), Tat can accelerate tumorigenesis by
vGPCR [22]. Thus, these facts led us to hypothesize that Tat may
participate in pathogenesis of AIDS-KS by influencing Kaposin A–
mediated tumorigenesis.
Therefore, we have explored the possible role of HIV-1 Tat in
Kaposin-A–induced NIH3T3 cell proliferation in vitro/tumorigenesis
in athymic nu/nu and immunocompetent mice.
Materials and Methods
Cells, Plasmids, and Transfection
NIH3T3 cells were maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM) containing 10% heat-inactivated fetal bovine serum,
2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin
(complete medium) at 37°C in a humidified, 5% carbon dioxide atmo-
sphere. To express KSHV–Kaposin A in NIH3T3 cells, a 169-bp
fragment of KSHVORF K12was obtained from BCBL-1 cells by poly-
merase chain reaction (PCR) [17] and inserted into the pcDNA3.1
plasmid vector (Invitrogen, Inc, Carlsbad, CA). To express HIV-1–Tat
in NIH3T3 cells, the pTat101 plasmid was used as described previously
[10]. The dominant-negative STAT3 construct (pMSCV-STAT3D-
EGFP, designated as STAT3-DN in this study) was kindly provided
by Dr. D. Link (Washington University School of Medicine, MO)
[23]. Transfections were performed with Lipofectamine 2000 reagent
(Invitrogen). Transfected cells were selected in G418 (Life Technologies,
Gaithersburg, MD), and resistant colonies were isolated after 2 to
3 weeks. Stable transfectant colonies were cloned by end point limit-
ing dilution.
Reverse Transcription–PCR
Reverse transcription–PCRs (RT-PCRs) were performed as described
previously [24]. Primers used for analysis in this study are listed in
Table 1.
Table 1. Sets of Primers Used in RT-PCR*.
mRNA Oligonucleotides Accession No. Expected Size (bp) Annealing Temperature (°C) Cycles
KSHV K12 F: 5′-ATG GAT AGA GGC TTA ACG GTG T-3′ NC_003409 169 56 35
R: 5′-TTG CAA CTC GTG TCC TGA ATG-3′
HIV-1 Tat F: 5′-ATG GCA GGA AGA AGC GGA GAC-3′ NC_001802 186 56 35
R: 5′-GTC GTC CTT GTA GTC GCC TC-3′
β-Actin† F: 5′-TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-3′ BC016045 661 56 19
R: 5′-CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG-3′
F indicates forward; R, reverse.
*The oligonucleotides were selected from the sequences with the indicated accession number. The size of each amplified product, its annealing temperature, and numbers of PCR cycles are indicated.
†These genes belong to human genome.
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Figure 1. Tat enhances proliferation of Kaposin A–transformed NIH3T3 cells. (A) RT-PCR analysis for Kaposin A and Tat mRNA in stable
transfectant colonies of NIH3T3 cells. Kaposin A and Tat mRNA expression in pcDNA3.1 vector (V), Kaposin A (Kap), Tat (Tat), or Kaposin
A plus Tat (K + T) stable transfectant colonies of NIH3T3 cells were detected by RT-PCR. M represents DNA molecular marker, and
β-actin was readily detectable in all samples indicating the presence of amplifiable complementary DNA. (B) Quantitation of soft agar
colony formation of four transfectants. After 21 days in culture, colony formation was scored by estimating the total number of colonies
with a diameter greater than 0.1 mm present in triplicate wells for pcDNA3.1 vector (V), Kaposin A (Kap), Tat (Tat), or Kaposin A plus Tat
(K + T) transfectant colonies of NIH3T3 cells. The results are expressed as the mean ± SD (n = 3). *P < .05 for Student’s t-test versus
Kap and Tat groups, respectively. (C) The 3H-TdR incorporation assay for cell proliferation detection of four transfectants. After serum
starving for 24 hours, the pcDNA3.1 vector (V), Kaposin A (Kap), Tat (Tat), or Kaposin A plus Tat (K + T) transfectants of NIH3T3 cells
were cultured in complete medium for 72 hours and labeled for the last 12 hours with 3H-TdR. The cells were collected, and the radio-
activity was measured by liquid scintillation counter. Data were expressed as the cpm of mean ± SD (n = 3). **P < .01 for Student’s
t-test versus Kap and Tat groups, respectively. (D) Flow cytometric analysis for cell cycle characteristics of four transfectants. After
serum starving for 24 hours, the pcDNA3.1 vector (V), Kaposin A (Kap), Tat (Tat), or Kaposin A plus Tat (K + T) transfectants of NIH3T3
cells were continued to culture in complete medium for 16 hours, then harvested and washed with PBS. The cell suspensions were
treated and stained with propidium iodide followed by flow cytometric analysis for cell cycle distribution. A representative experiment is
shown. The first peak corresponds to cells in G0/G1-phase, the intermediary population to cells in S-phase, and the second peak corre-
sponds to cells in the G2/M-phase. Very similar findings were observed in two repeat experiments.
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Soft Agar Assay
For analysis of colony formation, cell suspensions containing 0.3%
agar were seeded in each well of 24-well plates containing an underlay
of 0.6% agar in complete medium. Cultures were supplemented with
complete medium per week and colonies were scored 21 days after
seeding the cells.
Proliferation Assay
For the 3H-TdR incorporation, serum-starved cells were cultured
in complete medium for 72 hours and labeled for the last 12 hours
with 1 μCi of [3H]thymidine (3H-TdR; Institute of Radionuclide of
China, Beijing). Then, the cells were collected, and the radioactivity was
measured by liquid scintillation counter (Beckman, Fullerton, CA). All
the experiments were repeated independently at least three times on
96-well plates, and triplicate wells were used. The data represent the
mean counts per minute (cpm).
Flow Cytometry
After serum starving for 24 hours, cells continued to culture in com-
plete medium for 16 hours, then were harvested and washed three
times with PBS by centrifugation at 1000g for 5 minutes to remove
cell debris. The cell suspensions were fixed in ice-cold 75% ethanol
for 24 hours at −20°C. The samples were washed and resuspended in
PBS and then treated with 1% (vol/vol) Triton X-100 and 10 mg/ml
RNase A for 10 minutes at 37°C. Staining of cellular DNA was per-
formed with 20 mg/ml propidium iodide for 20 minutes at room tem-
perature in the dark. The percentage of the cells in the G0/G1, S, and
G2/M phases in the cell cycle were immediately analyzed by Flow
Cytometry (Coulter Becton-Dickinson, Miami, FL).
Antibodies
Anti-STAT3 rabbit polyclonal antibody (pAb), anti-VEGF rabbit
pAb, horseradish peroxidase–conjugated goat antimouse and antirabbit
immunoglobulin G were purchased from Santa Cruz Biotechnologies
(Santa Cruz, CA). Anti–phospho-STAT3 (Tyr705) rabbit monoclonal
antibody (mAb), anti–cyclinD1 rabbit mAb, anti–phospho–extracellular
signal–regulated protein kinase 1/2 (ERK1/2; Thr202/Tyr204) rabbit
pAb, anti–phospho-MEK1/2 (Ser217/221) rabbit pAb, anti–phospho
phosphatidylinositol 3-kinase (PI3K) [p85(Tyr458)/p55(Tyr199)] rab-
bit pAb, anti–phospho-Akt (Ser473) mouse mAb, and anti–Survivin
rabbit mAbs were obtained from Cell Signaling Technologies (Danvers,
MA). Anti–Akt rabbit pAbs were purchased from BioVision Incorpo-
rated (Mountain View, CA). Anti–ERK1/2 rabbit pAb were obtained
from KangChen Bio-tech (Shanghai, China). Mouse mAbs to β-actin
(Boster Technologies, Wuhan, Hubei, China) were used to monitor
sample loading.
Western Blot Analysis
After serum starving for 24 hours, cells were harvested and lysed in
rapid immunoprecipitation assay buffer containing a phosphatase in-
hibitor cocktail and protease inhibitors. Protein concentration was de-
termined using a Bradford Assay (Bio-Rad Laboratories, Hercules, CA).
Western blot analyses were performed as described previously [25,26].
Tumorigenicity Assay
Animal care and handling conformed to the Guide for Care and Use
of Laboratory Animals published by the US National Institutes of
Health, and the study was approved by Nanjing Medical University’s
ethical committee. The tumorigenic potential of stable transfectant
cells and cells isolated from induced tumor was tested in 3- to 4-week-
old male athymic BALB/c nu/nu mice (Shanghai Slac Laboratory Ani-
mal Center, Shanghai, China) and 3- to 4-week-old male BALB/c
immunocompetent mice (Laboratory Animals Center, Medical School
of Yangzhou University, Yangzhou, China), respectively, both of which
were housed under specific pathogen-free conditions. Stable transfectant
cells (2 × 106 cells per 200 μl of PBS per animal) were injected sub-
cutaneously (s.c.) behind the neck. Five mice were used in each group,
and experiments were performed twice. The nude mice were monitored
every day for the appearance of tumors. Tumor size was estimated as
the product of two-dimensional caliper measurements. Tumor-bearing
micewere killed, and tumors were formalin-fixed and paraffin-embedded
in their entireties. In addition, the tumors were minced, digested with
0.1% collagenase, and cultured in DMEM.Medium was changed every
3 days for 2 to 3 weeks with freshmedium containingG418. After reach-
ing confluence, G418-resistant cells were analyzed for Tat, Kaposin A
expression by RT-PCR. Then, the cells were injected s.c. into the right
flanks of BALB/c immunocompetent mice (2 × 106 per cells per 200 μl
of PBS per animal), and 10mice were used in each group. Themice were
monitored every day for the appearance of tumors, and tumor size was
estimated as described above.
Immunohistochemistry
Informative sections of formalin-fixed, paraffin-embedded tumor
from athymic BALB/c nu/nu mice were immunostained as described
elsewhere [27].
SuperArray Analysis
SuperArray analysis of gene expression was performed according to
the manufacturer’s directions (GEArray Q series Kit nonradioactive;
SuperArray, Inc, Bethesda, MD) and as described previously [10].
Statistical Analysis
All experiments were performed at least in triplicate. Numerical data
were expressed as mean ± SD. Two group comparisons were analyzed
by two-sided Student’s t-test. P values were calculated, and P < .05 was
considered significant.
Results
Tat Enhances Proliferation of Kaposin A–Transformed
NIH3T3 Cells
To generate stable transfectants, we transfected Kaposin A, Tat,
and Kaposin A plus Tat constructs into NIH3T3 cells. Stable transfec-
tants were selected, and expressions of target genes were examined by
RT-PCR. The mRNA of Kaposin Awas readily expressed in Kaposin A
alone or Kaposin A plus Tat–transfected NIH3T3 cells. Also, Tat mRNA
was expressed in Tat alone or in Kaposin A plus Tat–transfectedNIH3T3
cells (Figure 1A).
KSHVORF K12 coding for Kaposin A has been identified as a trans-
forming gene, which could induce not only cell proliferation in vitro
but also tumor formation in vivo [17]. To determine whether Tat can
influence NIH3T3 cells proliferation by Kaposin A, colony formation
assay was performed. As shown in Figure 1B, the percentage of colony
formation of Kaposin A plus Tat transfectants in NIH3T3 cells was
increased 1.51- (P < .05) and 1.94-fold (P < .05) compared with those
of Kaposin A and Tat transfectants, respectively. The 3H-TdR incorpo-
ration assay also demonstrated that Tat further enhanced proliferation
of Kaposin-transformed cells. As we could see in Figure 1C , the cpm
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Table 2. Expression of Gene Indicators for the Activation of 15 Different Signal Pathways Involved in Oncogenesis in Kaposin A–, Tat-, or Kaposin A Plus Tat–transfected NIH3T3 Cells and These Cells
Induced Tumor in Nude Mice.
Gene Function and Name Accession No. Fold Change When Compared with pcDNA3.1-Transfected NIH3T3 Cells (In Vitro) or pcDNA3.1-Transfected NIH3T3
Cells–Induced Tumor (In Vivo)
In Vitro In Vivo
Kaposin A Tat K + T Kaposin A Tat K + T
Androgen pathway
Cdk 2L NM_016756 1.47 0.82 0.85 1.11 1.36 0.96
p21Waf1/p21cip NM_007669 1.22 1.48 1.09 2.16 0.65 1.52
EGFR NM_007912 1.25 1.55 4.34 1.66 0.81 2.93
Folh1 NM_016770 1.68 1.69 4.49 0.54 0.88 1.02
Kallikrein 3 NM_008455 2.55 2.02 2.81 1.51 0.51 2.14
N4wbp4T/MEPAI NM_022995 1.08 1.22 1.59 1.02 1.13 1.81
Ngfa NM_010915 N/A N/A N/A 2.65 0.77 2.51
Cox-2 pathway
c-fos NM_010234 1.07 1.57 3.86 1.39 0.81 3.46
Hspa4 NM_008300 0.89 1.29 1.5 0.49 0.74 1.16
Mcl-1 NM_008562 1.35 1.52 1.92 0.43 0.72 1.14
Pparg NM_011146 1.73 1.19 1.82 6.86 17.77 2.16
Cox-2 NM_011198 1.38 1.11 4.28 0.52 0.41 0.66
TRAIL-R/DR5 NM_020275 1.32 0.27 0.73 1.74 3.99 1.57
DNA damage/p53 pathways
p21Waf1/p21cip NM_007669 1.22 1.48 1.09 2.16 0.65 1.52
Hspa4 NM_008300 0.89 1.29 1.5 0.49 0.74 1.16
Bax NM_007527 0.81 1.89 2.48 2.52 0.7 1.47
Bcl-2 NM_009741 0.81 2.14 2.34 2.74 1.29 3.17
Gadd45 NM_007836 5.82 5.28 5.09 0.82 2.22 0.91
Hif1a NM_010431 1.25 1.16 1.55 0.44 0.59 0.64
Ig f bp3 NM_008343 2.15 3.4 7.13 0.89 0.7 1.84
Mdm2 NM_010786 0.88 1.32 1.37 0.81 0.9 1.39
Fas NM_007987 0.44 0.33 0.33 2.52 0.76 2.75
Trail NM_009425 1.57 0.68 2.89 0.82 0.35 0.31
TRAF1 NM_009421 1.28 1.46 1.74 1.02 1.18 1.13
Wig1 NM_009517 1.51 1.96 2.44 0.9 0.8 1.01
Estrogen pathway
EGFR NM_007912 1.25 1.55 4.34 1.66 0.81 2.93
Bcl-2 NM_009741 0.81 2.14 2.34 2.74 1.29 3.17
BRCA1 NM_009764 0.57 1.49 4.44 1.64 0.95 2.4
Cathepsin D NM_009983 1.02 1.27 0.87 0.34 0.96 0.76
Progesterone receptor NM_008829 4.9 3.93 11.36 2.36 0.58 2.07
EFP/Zfp147 D63902 1.91 1.87 4.24 1.62 1 1.76
Hedgehog pathway
BMP2 NM_007553 3.82 3.5 5.96 5.42 0.78 5.91
BMP4 NM_007554 0.57 1.83 4.04 2.4 0.84 4.19
HNF3B/forkhead box A2 NM_010446 0.97 1.48 4.52 1.58 0.89 2.37
Hip NM_020259 2.62 1.94 3.13 0.68 0.8 0.76
Patched NM_008957 1.59 0.84 3.11 3.84 4.07 7.82
Patched 2 NM_008958 1.12 0.37 0.71 1.58 1.07 2.26
Wnt1 NM_021279 3.17 2.04 5.83 1.22 0.93 0.97
Wnt2 NM_023653 2.27 2 5.75 1.78 0.64 1.54
WSB-1 NM_019653 1.47 1.09 2.24 0.46 0.87 0.65
Hypoxia pathway
p21Waf1/p21cip NM_007669 1.22 1.48 1.09 2.16 0.65 1.52
Ig f bp3 NM_008343 2.15 3.4 7.13 0.89 0.7 1.84
Edn1 NM_010104 0.45 1.36 1.54 1.31 0.92 3.12
Epo NM_007942 2.79 2.71 3.77 1.42 0.69 1.06
Hk1 NM_010438 1.62 1.78 2.07 1.14 0.72 1.13
HMOX1 NM_010442 1.01 1.09 0.95 0.81 0.88 1.02
iNOS NM_010927 3.85 2.84 11.97 2.58 0.83 2.61
Glucose transporter 1 NM_011400 1.43 1.35 1.78 0.78 0.99 1.61
Transferrin NM_133977 2.89 2.06 4.92 1 0.96 1.03
Tfr1 NM_011638 0.98 0.93 1.06 0.35 0.89 0.81
VEGF/VEGI NM_009505 0.99 0.84 1.7 0.76 1.16 1.01
Inflammation/NF-κB pathways
iNOS NM_010927 3.85 2.84 11.97 2.58 0.83 2.61
ICAM-1 NM_010493 2.21 2.09 4.99 1.26 0.76 2.29
IL-2 NM_008366 0.85 1.2 1.17 0.83 0.86 1.29
TNFb NM_010735 5.71 4.33 10.65 1.46 0.55 1.31
NFkB1 NM_008689 3.22 2.17 4.52 2.13 0.74 2.69
ikBa/Mad3 NM_010907 2.13 2.17 2.93 1.52 1.18 1.63
TNFa NM_013693 4.73 3.83 15.54 1.49 0.56 1.92
VCAM-1 NM_011693 0.97 0.82 2.16 1.41 4.29 2.1
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Table 2. (continued )
Gene Function and Name Accession No. Fold Change When Compared with pcDNA3.1-Transfected NIH3T3 Cells (In Vitro) or pcDNA3.1-Transfected NIH3T3
Cells–Induced Tumor (In Vivo)
In Vitro In Vivo
Kaposin A Tat K + T Kaposin A Tat K + T
Mitogen-activated protein kinase pathway
c-fos NM_010234 1.07 1.57 3.86 1.39 0.81 3.46
Cola1 NM_007742 1.22 1.07 0.87 0.47 1.07 0.94
Krox-24 NM_007913 31.9 14.18 3.75 0.8 2.57 1.55
c-JUN NM_010591 1.41 1.79 2.43 0.94 1.16 2.33
PI3K/Akt pathways
Bcl-2 NM_009741 0.81 2.14 2.34 2.74 1.29 3.17
Hif1a NM_010431 1.25 1.16 1.55 0.44 0.59 0.64
Trail NM_009425 1.57 0.68 2.89 0.82 0.35 0.31
c-JUN NM_010591 1.41 1.79 2.43 0.94 1.16 2.33
Cyclin D1 NM_007631 1.02 0.7 0.98 0.95 1.32 0.98
Fn1 XM_129845 1.05 1.34 0.98 0.8 0.79 0.84
MMP7 NM_010810 2.32 1.05 1.07 0.64 21.65 1.46
c-myc NM_010849 1.49 1.06 2.94 1.12 2.81 1.61
STAT pathway
Bcl-2 NM_009741 0.81 2.14 2.34 2.74 1.29 3.17
iNOS NM_010927 3.85 2.84 11.97 2.58 0.83 2.61
Bcl-x NM_009743 1.22 4.14 10.84 3.4 1.36 4.1
Beta-casein NM_009972 2.81 2.52 3.42 1.45 0.59 0.94
MIG/Scyb9 NM_008599 1 1.91 2.68 2.95 0.95 2.61
IL-4 NM_021283 1.36 1.63 4.22 1.23 0.17 2.22
IL-4R NM_010557 6.68 1.57 2.4 0 4.44 0.1
IRF-1 NM_008390 0.98 1.27 0.99 0.14 1.89 1.03
Stromelysin 2 NM_019471 8.03 6.11 22.7 3.23 2.98 3.89
A1m NM_007376 5.95 3.33 10.52 1.63 0.51 1.38
Stress/heat shock pathways
Hspa4 NM_008300 0.89 1.29 1.5 0.49 0.74 1.16
Hsf1 (tcf5) NM_008296 1.06 1.35 2.9 0.62 0.54 1.65
Hsp25 NM_013560 6.68 4.7 4.28 0.79 1.73 1.07
Hspb2 NM_024441 1.02 1.07 0.96 0.9 0.92 0.94
Hsp86-1 NM_010480 0.88 1.01 0.92 0.61 0.84 0.82
Stress/p38 and JNK pathways
c-fos NM_010234 1.07 1.57 3.86 1.39 0.81 3.46
Hspa4 NM_008300 0.89 1.29 1.5 0.49 0.74 1.16
Cola1 NM_007742 1.22 1.07 0.87 0.47 1.07 0.94
c-myc NM_010849 1.49 1.06 2.94 1.12 2.81 1.61
Hsp25 NM_013560 6.68 4.7 4.28 0.79 1.73 1.07
Hspb2 NM_024441 1.02 1.07 0.96 0.9 0.92 0.94
ABCB4 NM_011076 0.9 0.82 0.82 9.5 4.13 9.69
ABCB1 NM_011075 1.04 0.81 0.68 3.23 1.44 4.86
CRE-BP/Creb2 NM_009715 1.4 1.51 1.5 0.81 0.93 2.09
Ptpn16 NM_013642 0.69 1.07 0.74 1.04 0.89 2.39
autotaxin (ATX) NM_015744 3.43 2.41 2.76 0.93 0.97 1.11
grp78 NM_022310 0.73 1.03 1.25 0.31 0.85 0.95
p53 NM_011640 1.74 0.83 2.44 5.56 9.97 1.06
Survival/NF-κB pathway
TRAF1 NM_009421 1.28 1.46 1.74 1.02 1.18 1.13
Bcl-x NM_009743 1.22 4.14 10.84 3.4 1.36 4.1
AKT-1 NM_009652 1.14 1.41 0.74 1.74 0.79 4.05
Bfl-1 NM_007536 0.57 2.62 6.14 1.28 1.56 1.6
NAIP1 NM_008670 0.92 0.43 0.44 2.46 2.92 2.96
NAIP2 NM_010872 1.05 0.67 0.72 2.32 1.3 2.02
NAIP5 NM_010870 0.94 1.17 0.78 1.23 1.25 1.39
IAP1 NM_007464 3.28 2.03 1.63 3.01 0.66 2.03
IAP2 NM_007465 1.38 3.84 5.8 2.3 1.9 1.38
TNFAIP3 NM_009397 1.87 0.26 1.77 N/A N/A N/A
TGF-β pathway
p21Waf1/p21cip NM_007669 1.22 1.48 1.09 2.16 0.65 1.52
p27Kip1 NM_009875 1.52 2.85 1.52 2.06 0.79 1.84
p57Kip2 NM_009876 1.04 1.96 2.46 3.32 0.89 1.91
p16 ink4a NM_009877 0.64 1.45 1.73 1.65 0.98 2.39
p15INK4b NM_007670 0.83 1.32 1.45 1.02 0.79 1.43
p18 NM_007671 0.92 1.2 1.33 0.79 0.97 1.13
p19 NM_009878 2.79 1.42 1.56 1.09 1.42 1.64
Wnt pathway
BMP 4 NM_007554 0.57 1.83 4.04 2.4 0.84 4.19
VEGF/VEGI NM_009505 0.99 0.84 1.7 0.76 1.16 1.01
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of Kaposin A plus Tat transfectants in NIH3T3 cells was increased 1.4-
(P < .01) and 2.54-fold (P < .01) compared with those of Kaposin A
and Tat transfectants, respectively. To further support this, cell cycle
profiles analysis showed that the control vector transfectant contained
approximately 30% of the cells in S-phase, whereas Kaposin A trans-
fectant was observed with approximately 46% of the cells in S-phase.
A similar profile was seen with Tat transfectant with approximately
43% of the cells in S-phase. Notably, Kaposin A plus Tat transfectant
had a slightly high proportion (approximately 50%) of cells in S-phase
(Figure 1D). Together, these data suggest that Tat may enhance NIH3T3
cells proliferation medicated by Kaposin A.
Tat Increases the MEK/ERK, STAT3, and PI3K/Akt Signals
by Kaposin A
Todetect which signaling pathwayswere activated byTat inKaposin A–
transduced NIH3T3 cells, we first detected gene expressing profile
changes affected by Kaposin A and/or Tat using microarray technique.
The Q Series signal transduction gene array in mouse cancer, which
Table 2. (continued )
Gene Function and Name Accession No. Fold Change When Compared with pcDNA3.1-Transfected NIH3T3 Cells (In Vitro) or pcDNA3.1-Transfected NIH3T3
Cells–Induced Tumor (In Vivo)
In Vitro In Vivo
Kaposin A Tat K + T Kaposin A Tat K + T
c-JUN NM_010591 1.41 1.79 2.43 0.94 1.16 2.33
Cyclin D1 NM_007631 1.02 0.7 0.98 0.95 1.32 0.98
MMP7 NM_010810 2.32 1.05 1.07 0.64 21.65 1.46
c-myc NM_010849 1.49 1.06 2.94 1.12 2.81 1.61
ABCB4 NM_011076 0.9 0.82 0.82 9.5 4.13 9.69
ABCB1 NM_011075 1.04 0.81 0.68 3.23 1.44 4.86
autotaxin (ATX) NM_015744 3.43 2.41 2.76 0.93 0.97 1.11
Fra1 NM_010235 0.78 1.25 1.9 1.14 1.13 2.34
ID2 NM_010496 1.15 1.27 1.24 0.84 0.94 1.21
Tcf1 NM_009327 5.17 3.65 12.01 1.13 0.65 1.67
ELM1 NM_018865 2.08 2.1 2.84 0.67 1.17 0.77
Figure 2. Enhanced activation of MEK/ERK, STAT3, and PI3K/Akt signals by Kaposin A and Tat in combination. (A, B, C) Activation of
MEK/ERK (A), STAT3 (B), and PI3K/Akt (C) signals in Kaposin A plus Tat–transfected NIH3T3 cells. After serum starving for 24 hours, the
pcDNA3.1 vector (V), Kaposin A (Kap), Tat (Tat), and Kaposin A plus Tat (K + T) transfectants of NIH3T3 cells were harvested and lysed
in RIPA buffer containing a phosphatase inhibitor cocktail and protease inhibitors. Lysates were subjected to SDS-PAGE, transferred to
membrane then immunoblotted with the indicated anti–phospho antibody. The membrane was stripped and reprobed with respective
antibody or with antiactin to confirm the equal amounts of protein in each sample. The phosphorylation levels in V group were consid-
ered to be 1 for comparison.
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profiles the expression of 113 gene indicators or markers belonging to
15 different signal pathways involved in oncogenesis, was used to screen
the potential signal pathway(s). As shown in Table 2, mRNA of many
gene markers of 15 different signal pathways in Kaposin A, Tat, and
Kaposin A plus Tat–transfected NIH3T3 cells were altered to some
degree compared with control vector–transfected NIH3T3 cells. Note-
worthy, mRNA of majority gene markers from mitogen-activated
protein kinase and STAT pathways were consistently increased more
than two-folds in Kaposin A plus Tat–transfected NIH3T3 cells com-
pared with the corresponding controls (Table 2). To further exam-
ine whether these pathways are really activated in Kaposin A plus
Tat–transfectedNIH3T3 cells,Western blot were performed.We found
that both Kaposin A and Tat alone failed to increase phosphorylated
forms ofMEK and ERK inNIH3T3 cells. However, their combination
(Kaposin A plus Tat) significantly elevated phosphorylation levels of
these two proteins (Figure 2A). Similarly, activation of STAT3 was
significantly enhanced in both Kaposin A and Kaposin A plus Tat–
transfected NIH3T3 cells, although Tat alone did not elevate phos-
phorylated STAT3 when compared with the corresponding control
(Figure 2B). Because the PI3K/Akt pathway was involved in cell prolif-
eration and tumor formation [28,29], we therefore measured protein
expression of PI3K and Akt. Neither Kaposin A nor Tat alone up-
regulated phosphorylated PI3K level. However, both Kaposin A and
Tat effectively elevated phosphorylated Akt in NIH3T3 cells. Inter-
estingly, we again found that Kaposin A and Tat in combination in
NIH3T3 cells significantly increased both PI3K and Akt phosphoryla-
tion levels, particularly for Akt. The increasewas up tomore than 10 folds
compared with the vector control (Figure 2C). Actually, the data from
microarray showed that half of mRNA of gene markers from PI3K/
Akt pathway were increased in Kaposin A plus Tat–transfected NIH3T3
cells compared with the corresponding controls (Table 2).
These data collectively suggest that Tat increases activation of the
MEK/ERK, STAT3, and PI3K/Akt signals by Kaposin A.
Tat Accelerates Tumorigenesis Mediated by Kaposin A in
Nude Mice
To further test whether Tat could influence tumorigenesis induced
by Kaposin A in vivo, we injected the transformed NIH3T3 cells into
Figure 3. Tat accelerates tumorigenesis medicated by Kaposin A in BALB/c nu/nu mice. Tumors were induced by s.c. injection with the
pcDNA3.1 vector- (V), Kaposin A– (Kap), Tat- (Tat), and Kaposin A plus Tat– (K + T) transfected NIH3T3 cells in nude mice as described
in Materials and Methods. (A) A Kaplan-Meier plot for the time of appearance of palpable tumors is shown. A log-rank analysis gave a
P value of .0015 for the comparison of K + T with Kap, Tat and control vector, and a P value of .0018 for the comparison of Kap with
control vector. The log-rank P values were .6654 for the comparison of Tat with vector and .0581 for the Kap with Tat, indicating that
there were no significant differences between these groups. (B) Plot of the volume of the tumors. The results are expressed as the mean
± SD (n = 5). *P < .05 and **P < .01 for Student’s t-test versus Kap and Tat groups, respectively. (C) Column diagram of average tumor
weight. Tumor-bearing mice were killed at day 30 after injections, and tumors were removed and weighed. Data reflect the mean ± SD.
**P < .01 for Student’s t-test versus Kap and Tat groups, respectively. (D) Representative mice at day 30 after injections with V-, Kap-, Tat-,
and K + T–transfected NIH3T3 cells, respectively, from left to right.
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nude mice for each construct. Mice were observed every day for the
appearance of tumors at the site of injection, and tumors were mea-
sured in two dimensions after they first became visible. As shown in
Figure 3A, tumors in three of the mice receiving cells transfected with
Kaposin A plus Tat construct were detectable by day 9 after inocu-
lation. The earliest appearance of a tumor in the Kaposin A group
was at day 14, by which time all mice from the Kaposin A plus
Tat group had detectable tumor. And only three of five nude mice
for Tat construct had detectable tumors at day 30, and the earliest
appearance of a tumor in the Tat group was at day 17 after inocula-
tion. As judged from the volume of the tumor, the tumor growth rate
was strikingly higher with the Kaposin A plus Tat group compared
with rates for Kaposin A, Tat, and control. The data are summarized in
Figure 3B. Tumors were removed at day 30, weighted and sectioned for
further analysis. Three tumors in mice injected with the control vector
weighed 0.07 ± 0.09 g, and three in the Tat group weighed 0.13 ±
0.13 g. The Kaposin A group had an average weight of 0.39 ± 0.20 g
and Kaposin A plus Tat group weighed 5.64 ± 1.71 g (Figure 3C). Rep-
resentative mice from four different groups at day 30 after inoculation
showed typical tumors in Figure 3D. Taken together, these data suggest
that Tat may accelerate and enhance tumorigenesis by Kaposin A in
nude mice.
Histologically, Kaposin A–transfected NIH3T3 cells induced high-
grade undifferentiated sarcomas, which was consistent with the previ-
ous report [17]. The tumor was characterized by hemorrhagic necrotic
foci, which was different in size and irregular in shape. Numerous
multinucleate huge cells, newly formed vessels, and scattered lympho-
cytes were seen in tumor sections (Figure 4A). Similar features were also
observed in the tumor induced by Kaposin A plus Tat–transfected
NIH3T3 cells. However, tumor necrosis range was more distinguish-
able, and more multinucleate huge cells, newly formed vessels, and
infiltration lymphocytes were found in Kaposin A plus Tat–induced
tumor (Figure 4A). Immunohistochemical staining demonstrated that
expression levels of cyclin D1, VEGF, and Survivin in tumor tissue from
mice of Kaposin A groupwere higher than those of vector and Tat groups
(Figure 4B). Similarly, expressions of these three proteins in tumor tissue
from of Kaposin A plus Tat mouse were elevated compared with vector
and Tat groups and slightly increased compared with Kaposin A group
(Figure 4B). These data suggest that Tat may increase expressions of
cyclin D1, VEGF, and Survivin by Kaposin A in mouse tumor tissues.
Again, the Q Series signal transduction gene array in mouse cancer
was used to detect the potential signal pathway(s) in tumor tissues. As
shown in Table 2, mRNA of many gene indicators for the activation
of 15 different signal pathways in Kaposin A, Tat, and Kaposin A
plus Tat–induced tumor tissue were also altered to some degree com-
pared with control vector–induced tumor tissue. Because Tat increased
the activation of the MEK/ERK, STAT3, and PI3K/Akt signals in
Kaposin A–transduced NIH3T3 cells (Figure 2, A–C), we further tried
to detect phosphorylation of these molecules in the tumor tissue.
Figure 4C demonstrated that phosphorylation levels of STAT3 and
ERK in Kaposin A–induced tumor tissue were higher than vector
and Tat groups. Phosphorylation levels of these two proteins in tumor
tissue from Kaposin A plus Tat mouse were also elevated compared with
those from vector and Tat groups and slightly increased compared with
those from Kaposin A group (Figure 4C). Together, these data suggest
that multiple signaling are likely involved in Tat-enhanced tumorigenesis
by Kaposin A.
Activation of STAT3 Partially Contributes to Tumorigenesis
by Kaposin A
STAT3 activation has been shown to enhance oncogenic potential of
multiple viruses such as Epstein-Barr virus, human T-cell lymphotropic
virus 1, and herpesvirus Saimiri [30–32]. Strong activation of STAT3
by Tat in Kaposin A–transduced cells suggests that STAT3 pathway
may be involved in tumorigenesis by Kaposin A or Kaposin A plus
Tat. To test this hypothesis, we first transiently transfected Kaposin A
and Kaposin A plus Tat transfectants with STAT3-DN construct or
pMSCV vector (the STAT3-DN construct was cloned in pMSCV vec-
tor), respectively, and then injected these cells into nude mice. As de-
scribed previously, mice were observed, and the tumors weremeasured in
two dimensions after they first became visible. Interestingly, we found
that the tumor growth rate of Kaposin A + STAT3-DN group was much
lower than that of Kaposin A + vector group (Figure 5). The earliest
appearance of a tumor in the Kaposin A + STAT3-DN group was at
day 15 after inoculation, but Kaposin A + vector group was at day 12.
However, we did not observe any difference in the tumor growth rate
between Kaposin A plus Tat + STAT3-DN and Kaposin A plus Tat +
vector groups (data not shown). These data suggest that activation of
STAT3 may, at least in part, contribute to tumorigenesis by Kaposin A,
not Kaposin A plus Tat.
Tat Also Accelerates Tumorigenesis by Kaposin A in
Immunocompetent Mice
To determine whether Kaposin A, Tat, or Kaposin A plus Tat–
induced tumors in nude mice can grow in immunocompetent mice,
the tumors were minced, digested with 0.1% collagenase, and cultured
in DMEM. G418-resistant cells were analyzed for Kaposin A and Tat
expression by RT-PCR. It was demonstrated that Kaposin A mRNA
was readily expressed in G418-resistant cells from Kaposin A and
Kaposin A plus Tat–induced tumor tissues and Tat mRNA was also
expressed in G418-resistant cells from Tat and Kaposin A plus Tat–
induced tumor tissues (data not shown). The cells were then injected
s.c. into the right flanks of BALB/c immunocompetent mice. The ani-
mals were monitored every day for the appearance of tumors. As shown
Figure 4. Hematoxylin-eosin and immunohistochemical staining for characteristic of tumor induced by Kaposin A and Tat (original magni-
fication, ×400). (A) Representative microscopic appearance of tumor tissues. Tumors were induced by s.c. injection with the pcDNA3.1
vector– (V), Kaposin A– (Kap), Tat- (Tat), and Kaposin A plus Tat– (K + T) transfected NIH3T3 cells in nude mice and were formalin-fixed and
paraffin-embedded in their entireties as described in Materials and Methods. Hematoxylin-eosin staining of representative tumor sections
showed hemorrhagic tumor necrotic foci and abundance of blood vessels in a selected area of tumor tissue. (B) Immunohistochemical
staining of cyclin D1, VEGF, and Survivin expressed in the tumor tissue from nude mice. Cyclin D1, VEGF, and Survivin expressed in the
tumor tissue of mice induced by the pcDNA3.1 vector– (V), Kaposin A– (Kap), Tat- (Tat), and Kaposin A plus Tat– (K + T) transfected NIH3T3
cells. (C) Immunohistochemical staining of phosphorylated STAT3 and ERK expression in tumor tissue from nude mice. Phosphorylated
STAT3 and ERK expressed in tumor tissue ofmice induced by the pcDNA3.1 vector– (V), Kaposin A– (Kap), Tat- (Tat), and Kaposin A plus Tat–
(K + T) transfected NIH3T3 cells.
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in Figure 6A, tumors in 5 of 10 immunocompetent mice receiving
cells fromKaposin A plus Tat–induced tumor in nudemice were detect-
able at day 14 after inoculation, and the earliest appearance of a tumor
in this group was at day 8. Furthermore, tumors in 4 of 10 animals
receiving cells from Tat-induced tumor were detectable at day 15 after
inoculation, and the earliest appearance of a tumor in this group was
at day 9. However, only 1 of 10 mice receiving cells from Kaposin A–
induced tumor in nude mice developed tumor by day 17 after ino-
culation. Expectedly, none of immunocompetent mice receiving cells
from control vector–induced tumor developed tumor by day 30 after
inoculation (Figure 6A). As judged from the volume of the tumor, the
tumor growth rate of Kaposin A plus Tat group was slightly higher
than that of the Tat group. However, it was significantly higher than
those of Kaposin A and control vector groups, which are summarized
in Figure 6B. These data collectively suggest that Tat can also accelerate
tumorigenesis mediated by Kaposin A in immunocompetent mice.
Discussion
The HIV-1 transactivator protein Tat has long been of particular interest
to investigators studying AIDS-KS pathogenesis [5,33]. On one hand,
Tat (including extracellular and intracellular Tat) suffices to reactivate
latent KSHV by activation of JAK/STATsignaling [10,34]. Full-length
Tat and a 13–amino acid peptide corresponding to the basic region of
Tat can specifically enhance the entry of KSHV into endothelial and
other cells, probably by concentrating virions on cell surface [35]. Con-
versely, Tat can act as a growth factor for KS-derived endothelial cells,
enhance angiogenesis, and promote KS progression [4,5,8], possibly in
part through synergy with or dysregulation of the expression of pro-
inflammatory cytokines [6–9]. Furthermore, by inducing activation of
NF-AT and NF-κB signals, Tat accelerates tumorigenesis by KSHV
vGPCR in vivo [22]. These data suggest that Tat plays an important role
in pathogenesis of AIDS-KS.
In this study, we investigated the potential of Tat to influence
tumorigenesis induced by Kaposin A and explored the possible mecha-
nisms by which Tat enhances Kaposin A–mediated tumorigenesis.
Our experiments provide the direct experimental evidence that Tat
not only enhances Kaposin A–induced NIH3T3 cells proliferation
in vitro but also accelerates tumorigenesis by Kaposin A in nu/nu mice.
Previous studies indicated that Kaposin A has multiple functions in
single-gene transfer assays [17,36–38]. It can induce focus formation
in Rat-3 cells and NIH3T3 cells and cause anchorage-independent
growth and loss of contact inhibition in NIH3T3 cells. Rat-3 cells
expressing Kaposin A are tumorigenic in nu/nu mice [17]. Here, we
confirmed that Kaposin A has the ability to promote proliferation of
NIH3T3 cells. When Tat was transfected into NIH3T3 cells expressing
Kaposin A, it significantly enhanced Kaposin A–induced cell prolifera-
tion, suggesting that there is a molecular interaction between Tat and
Kaposin A in vitro. Furthermore, when NIH3T3 cells coexpressing
Kaposin A and Tat were injected into nude mice, the onset of tumor
was earlier than those of NIH3T3 cells expressing Kaposin A or Tat
alone. Meanwhile, its tumor growth rate was significantly faster, and
the average weight was heavier than groups of Kaposin A or Tat alone,
suggesting that intracellular Tat accelerates and enhances Kaposin A–
induced tumorigenesis by an autocrine mechanism in vivo. KSHV
is found in B lymphocytes, macrophages, keratinocytes, fibroblasts,
Figure 5. Activation of STAT3 partially contributes to tumorigenesis
medicated by Kaposin A. Tumors were induced by s.c. injectionwith
the Kaposin A–transfected NIH3T3 cells transiently transfected with
STAT3-DN construct (Kap + STAT3-DN) or pMSCV vector (Kap +
Vector) in nude mice as described in Materials and Methods. Plot
of the volume of the tumors was drawn. The results are expressed
as the mean ± SD (n = 3). *P < .05 or **P < .01 for Student’s t-test
versus Kap + STAT3-DN group.
Figure 6. Tat accelerates tumorigenesis induced by Kaposin A in
BALB/c immunocompetent mice. (A) A Kaplan-Meier plot for the
time of appearance of palpable tumors is shown. Tumors were in-
duced by s.c. injection with the cells derived from the pcDNA3.1
vector– (V), Kaposin A– (Kap), Tat- (Tat), and Kaposin A plus Tat–
(K+ T) induced tumor tissues in nudemice as described inMaterials
and Methods. A log-rank analysis gave P values of .0117 and .0429
for the comparison of K + T with control vector and Kaposin A, re-
spectively. The log-rank P values were .5197 for the comparison of
Tat with K + T and .1074 for the Kaposin A with Tat, indicating that
there were no significant differences between these groups. (B) Plot
of the volume of the tumors.
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epithelial cells, KS tumor cells, and endothelial cells [39]. By contrast,
the predominant host cells for HIV-1 are CD4+ T lymphocytes, den-
dritic cells, and mononuclear phagocytes [40,41]. Although HIV-1
and KSHV generally do not infect the same cell, cells infected by the
two viruses are often in close proximity. Tat is secreted from infected
cells (namely, extracellular Tat) and can bind to both αvβ3 and α5β1
integrins on the surface of target cells initiating intracellular signals that
ultimately lead to changes in cellular gene expression [4,33]. Conversely,
the extracellular Tat nonspecifically binds to cells membranes and is
internalized [5,42]. Like intracellular Tat, this internalized Tat may di-
rectly interact with cellular genes to alter gene expression. Here, we just
evaluated the potential of intracellular Tat to influence Kaposin A–
mediated tumorigenesis. However, whether by a paracrine mechanism
extracellular Tat may also have such function is still unknown.
In the current study, Tat was observed to enhance the proliferation
of Kaposin A–transformed cells with both colony formation in soft agar
and 3H-TdR incorporation assays. Although cell cycle analysis showed
a slightly increasing trend in S-phase of Kaposin A plus Tat transfectant,
it did not seem to reveal a significant difference compared with Tat or
Kaposin A alone. We pondered that the S-phase alone of cell cycle,
which represents DNA synthesis ability, was not only one index for
evaluation of cell proliferation. It was a complicated process and needed
the multiplicity factors to be involved in. Furthermore, Tat drastically
increased the MEK/ERK, STAT3, and PI3K/Akt signals by Kaposin A.
With regard to signaling activated by Kaposin A, a previous study in-
dicated that the transforming and adhesion effects of Kaposin A are
mediated through its association with cytohesin-1, a guanine nucleotide
exchange factor for ARF GTPases, which regulates integrin activity
and is important for transformation [36]. In fact, a dominant-negative
cytohesin-1–inhibited Kaposin A induced focus formation and restored
normal actin organization. As for Tat, it can not only increase spindle
cells viral load and expression of various viral genes with oncogenic
potential (vGPCR, vBCL2, and viral interferon-regulatory factor 1)
[11] but also activate multiple signaling pathways and has many func-
tions on AIDS-KS pathogenesis. For instance, NF-AT and NF-κB sig-
naling activated by KSHV vGPCR are synergistically increased by Tat
and Tat can accelerate tumorigenesis induced by vGPCR. The effects
of both vGPCR and Tat on signaling are dependent on the PI3K/Akt
pathway [22,43]. Here, we found that Kaposin A alone upregulates
phosphorylated Akt and STAT3, both of which are involved in cell pro-
liferation and tumor formation [28,29,44]. Furthermore, Tat increases
STAT3, PI3K/Akt, and MEK/ERK signaling activated by Kaposin A
both in vitro and in vivo. Actually, the data from microarray demon-
strated mRNA of many gene indicators for the activation of 15 different
signal pathways in both cells and tumor tissues were altered to some
degree. Therefore, our results did not eliminate the possibility that
other pathway(s) may also be involved in Tat-accelerated tumorigenesis
by Kaposin A.
In addition, we also found that Tat accelerated Kaposin A–
medicated tumorigenesis in immunocompetent mice. Recent stud-
ies by Thirunarayanan et al. [45] reported that vGPCR-expressing
cells established from tumors, which were induced with retrovirus-
transduced vGPCR-expressing NIH3T3 cells in nude mice, gave rise
to tumors in immunocompetent mice. Here, Kaposin A plus Tat-
expressing cells established from tumors induced with Kaposin A
plus Tat–expressing NIH3T3 cell lines in nude mice gave rise to
tumors with 50% incidence. Unexpectedly, the tumor incidence of
Kaposin A–expressing cells in immunocompetent mice was only 10%;
however, Tat was 40%. Noteworthy, the time of tumor formation of
Kaposin A plus Tat group was earlier, and tumor size was bigger than
those of Kaposin A or Tat groups in immunocompetent mice. On
one hand, rapid growth of subcutaneously injected Kaposin A plus
Tat–expressing cells established from nude mice tumors in immuno-
competent hosts probably was attributed to failure of the tumor cells
to reach organized lymphoid organs resulting in the insufficient presenta-
tion of the tumor associated antigens [46]. Conversely, the ability of
Kaposin and Tat–coexpressing NIH3T3 cells to survive immune surveil-
lance could be a result of as yet unknown immunomodulatory effects of
Tat, and also othermolecular changes occurred during tumor progression.
In summary, we have shown that Tat could accelerate tumorigenesis
induced by Kaposin A, and several signal pathways were involved in this
process. Because both Tat and Kaposin A can activate multiple signaling
pathways in vitro and in vivo, further studies are needed to understand
which signal is a key signal to control Tat–accelerated tumorigenesis by
Kaposin A in vivo.
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